APA-viite

Capehorn, M., Hallén, N., Baker-Knight, J., Glah, D., & Hunt, B. (2021). Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Ther.

Chicago-tyylinen lähdeviittaus

Capehorn, Matthew, Nino Hallén, James Baker-Knight, Divina Glah, ja Barnaby Hunt. "Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients With Type 2 Diabetes in the UK Setting." Diabetes Ther 2021.

MLA-viite

Capehorn, Matthew, et al. "Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients With Type 2 Diabetes in the UK Setting." Diabetes Ther 2021.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.